Expression of THOP1 and Its Relationship to Prognosis in Non-Small Cell Lung Cancer

Lei Qi, Shu-hai Li, Li-bo Si, Ming Lu, Hui Tian*

Department of Thoracic Surgery, Qilu Hospital, Shandong University, Jinan, Shandong Province, China

Abstract

Background: The study was designed to detect the expression level of thimet oligopeptidase (THOP1) protein in non-small cell lung cancer (NSCLC) and investigate its correlation with clinicopathologic features and prognosis.

Methods: Immunohistochemical staining was used to determine the expression of THOP1 protein in 120 NSCLC specimens and 53 distant normal lung tissues. Quantitative real-time PCR and western blotting were employed to measure the expression of THOP1 in 16 pairs of primary NSCLC and corresponding normal tissues.

Results: Analysis of immunohistochemical staining suggested low THOP1 expression was found in 71 (59.2%) of the 120 NSCLC specimens and significantly correlated with positive lymph node metastasis (P = 0.048). However, low THOP1 expression was found in 22 (41.5%) of the 53 normal lung tissues. Chi-square test suggested that the expression of THOP1 was significantly higher in the normal lung tissues than that in the NSCLC specimens (P = 0.032). Real-Time PCR and western blotting showed that NSCLC specimens had decreased THOP1 mRNA and protein expression compared to corresponding normal tissues. Univariate analysis demonstrated that low THOP1 expression significantly predicted decreased 5-year disease-free survival (P = 0.038) and overall survival (P = 0.017). In addition, positive lymph node metastasis (P = 0.025) and advanced TNM stage (P = 0.009) significantly predicted decreased 5-year overall survival. However, multivariate Cox regression analysis showed that only low THOP1 expression retained its significance as an independent prognostic factor for unfavorable 5-year disease-free survival (P = 0.046) and overall survival (P = 0.021).

Conclusions: THOP1 may have clinical potentials to be employed as a promising biomarker to identify individuals with better prognosis and a novel antitumor agent for therapy of patients with NSCLC.

Introduction

Non-small cell lung cancer (NSCLC) is one of the most common intrathoracic malignancies throughout the world due to its late clinical presentation and rapid progression [1,2]. Despite some advances in early detection and radical surgical resection combined with adjuvant therapy over the recent decade, the prognosis of NSCLC patients remains relatively poor [3]. It is generally acknowledged that genetic heterogeneity and environmental factors lead to tumorigenesis of lung cancer simultaneously. Therefore, identification of novel prognostic biomarkers with possible therapeutic and prognostic relevance is important to optimize the treatment of NSCLC.

Thimet oligopeptidase (THOP1; EC3.4.24.15 or EP 24.15) is a characteristic metallopeptidases with a HEXXH zinc binding motif and associated with metabolism of several neuropeptides containing from 5 to 17 amino acids, such as bradykinin, gonadotropin releasing hormone, opioids and neurotensin [4,5,6]. Accumulated evidence suggested that THOP1 was predominately expressed in the cytosol, endoplasmic reticulum, mitochondria and nucleus of different normal human tissues and tumor cells [7,8,9]. Moreover, immunohistochemical analysis indicated that THOP1 was present in 90% of NSCLC cell line H1299 and secreted by the cells to cleave and activate DTS-201 [10]. Recent study demonstrated that high THOP1 mRNA expression level in the normal background liver of hepatocellular carcinoma (HCC) was significantly correlated with better survival [11]. Furthermore, THOP1 could inhibit tumor angiogenesis and tumor proliferation promoted by BK in melanoma cells [12]. These findings indicate THOP1 may be a potential anti-tumor agent for tumor therapy.

Expression of THOP1 and its role in prognosis of NSCLC has not been investigated so far. Therefore, we detected expression levels of THOP1 protein in patients with NSCLC by employing immunohistochemical method to investigate its correlation with
Materials and Methods

Ethics Statement
This study was approved by the Ethics Committee of Qilu Hospital. Written informed consent was obtained from each patient to publish the case details, and acquisition of tissue specimens was carried out as prescribed by the institutional guidelines.

Patients
Tumor samples (n = 120, mean age 61 ± 4.35 years) and distant normal lung tissues (n = 53, 5 cm from the margin of the tumor) were collected from patients with NSCLC who underwent complete tumor resection (lobectomy or pneumonectomy) with regional lymph node dissection between January 2006 and December 2007 at the department of Thoracic Surgery, Qilu Hospital. Histologic examination and grade of cancer cell differentiation were based on the classification system of World Health Organization revised in 2004 and TNM staging system of UICC 2009. No patients had undergone incomplete resection and received chemotherapy or radiation therapy before surgery. The clinical characteristics of these 120 patients are presented in Table 1.

Immunohistochemistry
Immunohistochemical staining for THOP1 was carried out using the streptavidin-peroxidase method. In brief, 4-µm-thick sections were cut from paraffin-embedded blocks, deparaffinized in xylene and dehydrated through a series of graded alcohol. The sections were incubated in citrate buffer (pH 6.0) with a microwave oven. After be cooled to room temperature, the slides were incubated in 3% hydrogen peroxide for 15 min to block endogenous peroxidase activity and incubated with a mouse monoclonal antibody against THOP1 (Abcam, Cambridge, MA, USA, dilution 1:50) overnight at 4°C. Subsequently, the biotinylated secondary antibody and peroxidase-conjugated streptavidin complex reagent were applied, followed by counterstaining with Mayer’s hematoxylin. Positive and negative controls were included in each step.

Table 1. Correlation of clinicopathologic variables with THOP1 protein in NSCLC.

| Category            | No. of patients | THOP1 high | THOP1 low | P*  |
|---------------------|-----------------|------------|-----------|-----|
| Age                 |                 |            |           | 0.539 |
| ≤60 years           | 67              | 29         | 38        |     |
| ≥60 years           | 53              | 20         | 33        |     |
| Sex                 |                 |            |           | 0.611 |
| Male                | 67              | 26         | 41        |     |
| Female              | 53              | 23         | 30        |     |
| Smoking history     |                 |            |           | 0.300 |
| Yes                 | 52              | 24         | 28        |     |
| No                  | 68              | 25         | 43        |     |
| Histology           |                 |            |           | 0.826 |
| SCC                 | 70              | 28         | 42        |     |
| Adeno               | 50              | 21         | 29        |     |
| Differentiation     |                 |            |           | 0.247 |
| Well                | 31              | 8          | 23        |     |
| Moderate            | 58              | 24         | 34        |     |
| Poor                | 31              | 17         | 14        |     |
| Tumor size          |                 |            |           | 0.117 |
| ≤3 cm               | 51              | 25         | 26        |     |
| >3 cm               | 69              | 24         | 45        |     |
| Lymph node metastasis|               |            |           | 0.048 |
| N0                  | 60              | 29         | 29        |     |
| N1, N2              | 73              | 20         | 42        |     |
| TNM stage           |                 |            |           | 0.491 |
| Stage I             | 47              | 21         | 26        |     |
| Stage II and III    | 73              | 28         | 45        |     |

*aChi-square test.
SCC squamous cell cancer.
Adeno adenocarcinoma.
doi:10.1371/journal.pone.0106665.t001
Figure 1. Immunohistochemical staining for THOP1 in NSCLC specimens. Various intensities of THOP1 protein expression in adenocarcinoma, negative expression (A), with weak (B), moderate (C), and strong (D) expression. Various intensities of THOP1 protein expression in squamous cell cancer, negative expression (E), with weak (F), moderate (G), and strong (H) expression.

doi:10.1371/journal.pone.0106665.g001
Evaluation of THOP1 Protein Expression

The immunostained slides were evaluated by two independent investigators in a blinded fashion and reevaluated by these investigators under a multihead microscope in discordant cases to reach a consensus. Expression of the THOP1 protein were evaluated by calculating a total immunostaining score as the product of both the intensity score (0, negative staining; 1, weak staining; 2, moderate staining; 3, strong staining) and proportion score (0, 0–5%; 1, 6–25%; 2, 26–50%; 3, 51–75%; 4, ≥76%), respectively. Thus, the total score ranged from 0 to 7. The cutoff value for high and low THOP1 expression was determined based on a heterogeneity value measured through a log-rank statistical analysis with respect to overall survival. The percentile that yielded the minimum P value was chosen as cutoff point [13]. In brief, the 120 patients were arranged in order of the total staining score detected by immunohistochemical analysis from big to small. At each percentile from 10 to 90, the data were divided into two groups and the differences in overall survival were analyzed using the log-rank test. The 41st percentile corresponding to the total staining score of 4 yielded the minimum P value (P = 0.017) and was chosen as the cutoff point. Therefore, the total staining score of 4 was chosen as the cutoff point for the discrimination between high and low THOP1 expression. Tumors with a total staining score ≥4 were all defined as high THOP1 expression, and tumors with a total staining score <4 were all defined as low THOP1 expression.

RNA Extraction, Reverse-Transcription Polymerase Chain Reaction and Quantitative Real-Time PCR

Total RNAs were extracted from tissues by using the Trizol (Invitrogen, Carlsbad, CA, USA). Complementary DNA (cDNA) was synthesized by SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA). Quantitative real-time PCR was carried out by using SYBR Green Supermix (Bio-Rad, CA, USA) for THOP1 according to the manufacturer’s instructions. The levels of THOP1 messenger RNA (mRNA) were normalized to the human β-actin expression level and calculated using the 2^(-ΔΔCT) method. Primers were used as the following: sense: The primers for β-actin were: 5′-GCATCCAGGAATCTACCT-3′ (forward) and 5′-GAAAGGTTGTAACGCCAAC-3′ (reverse); THOP1 primers were: 5′-CAT GGC CAA GAC CAG CCA GA-3′ (forward) and 5′-GGC ACG CTT CAG CTC CAG AA-3′ (reverse).

SDS-PAGE and Western Blot

Proteins were extracted using RIPA lysis buffer. Equal amounts (20 μg) of protein were subjected to SDS-PAGE analysis, transferred onto nitrocellulose membranes and probed with primary antibodies. Antibody against THOP1 was purchased from Abcam (Abcam, Cambridge, MA, USA, dilution 1:1000). Anti-β-actin antibody was purchased from Sigma (Sigma, St. Louis, USA). Protein bands were detected using the enhanced chemiluminescence method (Millipore, Billerica, MA, USA). The optical band density was quantified (Imager of Alpha Corporation, San Leandro).

Follow up

All patients discharged from hospital were followed-up at the outpatient clinic every 3 to 6 months. Follow-up evaluation of patients consisted of physical examination, blood tests, computed tomography, ultrasound examination, chest X-ray, and fiberoptic bronchoscopy if necessary. The location and time of tumor relapse were recorded. Follow-up was completed in all patients until December 2013, and the median follow-up period was 48 months (range: 15–96 months).

Statistical Analysis

Statistical analysis of data was performed by SPSS 17.0 system. Chi-square test was performed to examine the association of THOP1 and various clinicopathologic factors. Follow-up time was censored if the patient was lost to follow-up. Survival curves were drawn using the Kaplan-Meier method and compared by the log-rank test. Multivariate Cox regression analysis was used to identify significant independent prognostic factors. All data are mean ± standard deviation (SD) from independent assays. Other statistical analyses were performed using a Student’s t-test. P < 0.05 was considered to be statistically significant.

Results

1. Expression of THOP1 in NSCLC and its correlation with clinicopathologic factors

We detected the expression of THOP1 protein in 120 NSCLC specimens and 53 normal lung tissues using immunohistochemistry. As shown in Fig. 1, immunohistochemistry with THOP1 antibodies showed a positive reaction in the cytoplasm of NSCLC cells. According to our earlier defined criteria, high THOP1 expression was found in 49 (40.8%) of the 120 tumor specimens.
Figure 3. Real-time PCR and Western blot analysis of THOP1 expression in NSCLC. A. Expression of THOP1 mRNA in the NSCLC tissues was lower than that in the normal lung tissues ($P<0.01$). B. Western blot analysis suggested that NSCLC specimens had decreased THOP1 protein expression compared to corresponding normal tissues. N: Normal lung tissue, T: NSCLC specimens.

doi:10.1371/journal.pone.0106665.g003
and low THOP1 expression was found in 71 (59.2%) of the 120 tumor specimens. In addition, as negative controls, immunostaining without primary antibodies resulted in no staining. As shown in Fig. 2, THOP1 was highly expressed in the cytoplasm of normal bronchial epithelium cells and pneumocytes. High THOP1 expression was found in 31 (58.5%) of the 53 normal lung tissues and low THOP1 expression was found in 22 (41.5%) of the 53 normal lung tissues. The expression of THOP1 was significantly higher in the normal lung tissues than that in the NSCLC specimens (chi-square test, \( P = 0.032 \)).

Relationships between THOP1 protein expression and clinicopathologic factors were examined by chi-square test, and our data showed that lower THOP1 expression was significantly correlated with positive lymph node metastasis (\( P = 0.048 \)). There was no statistical significance in relationships between THOP1 expression and other clinicopathologic variables (\( P > 0.05 \), Table 1).

To investigate the expression of THOP1 gene in NSCLC, we used Quantitative Real-Time PCR to measure the expression of THOP1 mRNA levels in 16 pairs of primary tumors and corresponding normal tissues. Compared to their corresponding normal tissues, NSCLC specimens had decreased THOP1 mRNA expression (Figure 3A). Consistently, western blotting analysis showed that 12 of 16 NSCLC specimens had decreased THOP1 protein expression compared to their corresponding normal tissues (Figure 3B).
2. Univariate and multivariate survival analysis for 5-year disease-free survival

Tumor relapse developed within the follow-up period in 82 (68.3%) of the 120 patients: local recurrence in 18 patients, distant metastasis in 52 patients, and both local recurrence and distant metastasis in 12 patients. Univariate analysis (log-rank test) demonstrated that low THOP1 expression (25.4% versus 40.8%, \( P = 0.038 \), Figure 4A) significantly predicted decreased 5-year disease-free survival. Moreover, the results of multivariate Cox regression analysis showed that low THOP1 expression retained its significance as an independent prognostic factor for unfavorable 5-year disease-free survival (\( P = 0.046 \), Table 2).

3. Univariate and multivariate survival analysis for 5-year overall survival

Of the 120 patients, 73 (60.8%) cases died of cancer-related causes within 5 years after operation, the 5-year overall survival was 39.2%. Univariate analysis (log-rank test) demonstrated that low THOP1 expression (29.6% versus 53.1%, \( P = 0.017 \), Figure 4B), positive lymph node metastasis (29.0% versus 50.0%, \( P = 0.025 \), Figure 4C) and advanced TNM stage (30.1% versus 53.2%, \( P = 0.009 \), Figure 4D) significantly predicted poor 5-year overall survival (Table 3). The results of multivariate Cox regression analysis showed that the significant prognostic effect of positive lymph node metastasis (\( P = 0.653 \), Table 3) and advanced TNM stage (\( P = 0.218 \), Table 3) observed on univariate analysis disappeared, and only low THOP1 expression retained its significance as an independent prognostic factor for unfavorable overall survival (\( P = 0.021 \), Table 3).

### Discussion

Although being considered to play a role in the neuroendocrine system [14], THOP1 has become a recent focus in tumor research. Cell fractionation studies have demonstrated that THOP1 is present in the particulate subcellular fractions of the central nervous tissue [15] and secreted from distinctive cell lines, such as the rat glioma C6 [16] and mouse AtT-20 [17]. Moreover, high THOP1 mRNA expression in corresponding normal tissue of hepatocellular carcinoma (HCC) was correlated with a better overall survival [11]. However, few studies have detected the

| Table 2. Univariate and multivariate analysis for disease-free survival. |
|---------------------------|---------------------------|---------------------------|
| **Variable** | **Univariate analysis** | **Multivariate analysis** |
|              | \( P \)          | 95% CI          | Exp(B)    | \( P \)       |
| Sex (Male vs Female) | 0.317          | 0.790–1.963    | 1.245     | 0.346        |
| Age (<60 years vs \( \geq 60 \) years) | 0.725          | 0.527–1.318    | 0.833     | 0.435        |
| Smoking (Yes vs No) | 0.791          | 0.780–2.058    | 1.267     | 0.338        |
| Histology (SCC vs Adeno) | 0.284          | 0.789–1.977    | 1.249     | 0.343        |
| Differentiation (Poor vs Moderate vs Well) | 0.763          | 0.743–1.411    | 1.024     | 0.884        |
| Tumor size (\( \leq 3 \) cm vs >3 cm) | 0.061          | 0.822–2.141    | 1.327     | 0.247        |
| Lymph node metastasis (N0 vs N1 and N2) | 0.092          | 0.630–2.694    | 1.303     | 0.475        |
| TNM (Stage I vs Stage II and III) | 0.109          | 0.514–2.344    | 1.097     | 0.810        |
| THOP1 (High vs Low) | 0.038          | 0.366–0.990    | 0.602     | 0.046        |

CI confidence interval.
SCC squamous cell cancer.
Adeno adenocarcinoma.
doi:10.1371/journal.pone.0106665.t002

| Table 3. Univariate and multivariate analysis for overall survival. |
|---------------------------|---------------------------|---------------------------|
| **Variable** | **Univariate analysis** | **Multivariate analysis** |
|              | \( P \)          | 95% CI          | Exp(B)    | \( P \)       |
| Sex (Male vs Female) | 0.993          | 0.632–1.633    | 1.016     | 0.947        |
| Age (<60 years vs \( \geq 60 \) years) | 0.708          | 0.604–1.558    | 0.970     | 0.900        |
| Smoking (Yes vs No) | 0.845          | 0.881–2.394    | 1.452     | 0.144        |
| Histology (SCC vs Adeno) | 0.189          | 0.820–2.136    | 1.324     | 0.251        |
| Differentiation (Poor vs Moderate vs Well) | 0.866          | 0.789–1.574    | 1.114     | 0.539        |
| Tumor size (\( \leq 3 \) cm vs >3 cm) | 0.070          | 0.768–2.118    | 1.275     | 0.348        |
| Lymph node metastasis (N0 vs N1 and N2) | 0.025          | 0.557–2.545    | 1.191     | 0.653        |
| TNM (Stage I vs Stage II and III) | 0.009          | 0.735–3.854    | 1.683     | 0.218        |
| THOP1 (High vs Low) | 0.017          | 0.312–0.911    | 0.533     | 0.021        |

CI confidence interval.
SCC squamous cell cancer.
Adeno adenocarcinoma.
doi:10.1371/journal.pone.0106665.t003
expression of THOP1 protein in tumor tissues and its relationship to tumor prognosis.

In the present study, we investigated the expression of THOP1 in NSCLC and corresponding normal tissues, and then analyzed the relationships between THOP1 expression and other clinicopathologic variables in NSCLC. The findings of our study showed that THOP1 was universally expressed in NSCLC and corresponding normal tissues, and expression of THOP1 in normal tissues of NSCLC was significantly elevated in both mRNA and protein levels. In addition, lower THOP1 expression in NSCLC was significantly correlated with positive lymph node metastasis. Kaplan-Meier analysis in this study showed that low THOP1 expression significantly predicted decreased 5-year disease-free survival and overall survival. In addition, positive lymph node metastasis and advanced TNM stage significantly predicted decreased 5-year overall survival. To eliminate the impact of mixed factors correlated with prognosis on statistical analysis, the Cox regression multivariate analysis was performed to determine independent prognostic factors. Multivariate analysis showed that only THOP1 maintained its prognostic value as independent prognostic factor for poor disease-free and overall survival.

Our survival analysis demonstrated that the expression of THOP1 protein could be a useful diagnostic marker for patients with NSCLC. As stated above, our results implied that THOP1 protein may have an antitumor effect in carcinogenesis and tumor progression of NSCLC.

Previous study suggested that THOP1 could be an ideal hydrolyze several kinds of bioactive peptides such as bradykinin (BK) [18]. BK is an important mediator responsible for tumor-associated angiogenesis and cancer progression by increasing integrin expression through the BK receptor signal pathway [22]. Moreover, as an antagonist factor to BK, THOP1 could inhibit angiogenesis and tumor growth promoted by BK [12]. Pathological angiogenesis is a relatively early event in the carcinogenesis and increased tumor angiogenesis is correlated with tumor invasion, metastasis and poor prognosis [23,24]. Therefore, decreased expression of THOP1 in NSCLC may be responsible for cancer development, malignancy and poor survival rate due to its reduction in anti-BK function.

Exciting progress has been made in employing THOP1 for immunotherapy in cancers. It was reported that THOP1 secreted by tumor cells was a very likely candidate for the extracellular activation of CPI-004Na which was a prodrug of doxorubicin, and the improved therapeutic index of CPI-004Na compared with free doxorubicin was confirmed in three tumor xenograft models of prostate, breast, and lung cancer [10,25]. Another study about cytotoxic T lymphocytes (CTL) suggested THOP1 could strengthen the immune defense against intracellular pathogens and cancer by contributing to the C-terminal trimming of CTL epitopes [26]. Therefore, THOP1 may have clinical potential to be employed as a more useful agent of antitumor therapy for patients with NSCLC.

In conclusion, our retrospective analysis provided evidence that the expression of THOP1 was significantly higher in the normal lung tissues than that in the NSCLC specimens, and low THOP1 expression was significantly correlated with positive lymph node metastasis in NSCLC. Moreover, high THOP1 protein expression exhibited antitumor property and showed positive influence on both disease-free and overall survival. Therefore, THOP1 may have clinical potentials to be employed as a promising biomarker to identify individuals with better prognosis and a novel antitumor agent for therapy of patients with NSCLC.

Author Contributions
Conceived and designed the experiments: HT. Performed the experiments: LQ, SHL, ML. Analyzed the data: LQ, SHL. Contributed reagents/materials/analysis tools: LBS. Contributed to the writing of the manuscript: LQ, HT.

References
1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137–2153.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 223–249.
3. Pisters KM, Evans WK, Azoldi CG, Kris MG, Smith CA, et al. (2007) Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIB resectable non-small-cell lung cancer guideline. J Clin Oncol 25: 5506–5518.
4. Camargo AC, Gomes MD, Reichl AP, Ferro ES, Jacchieri S, et al. (1997) Structural features that make oligopeptides susceptible for hydrolysis by recombinant thimet oligopeptidase. Biochem J 324 (Pt 3): 517–522.
5. Montel JL, Cortalle F, Roques BP, Noble F (1997) Nociceptin/orphanin FQ metabolism: role of aminopeptidase and endopeptidase 24.15. J Neurochem 68: 354–361.
6. Oliveira V, Campos M, Melo RI, Ferro ES, Camargo AC, et al. (2001) Substrate specificity characterization of recombinant metallo-oligopeptidases thimet oligopeptidase and neurolysin. Biochemistry 40: 4417–4423.
7. Barrett AJ, Brown MA, Dando PM, Knight CG, McKie N, et al. (1995) Thimet oligopeptidase and oligopeptidase M or neurolysin. Methods Enzymol 246: 529–536.
8. Krause DR, Pica TJ, Brown SB, Ellem KA (1997) Characterization and localization of mitochondrial oligopeptidase (MOP) (EC 3.4.24.16) activity in the human cervical adenocarcinoma cell line HeLa. J Cell Biochem 66: 297–308.
9. Masarelli EE, Casati CA, Kato A, Camargo AC, Bauer JA, et al. (1999) Differential subcellular distribution of neurolysin (EC 3.4.24.16) and thimet oligopeptidase (EC 3.4.24.15) in the rat brain. Brain Res 851: 261–265.
10. Ravel D, Dubois V, Quinonero J, Meyer-Losic F, Delord J, et al. (2008) Preclinical toxicity, toxicokinetics, and antimicrobial efficacy studies of DTs-201, a tumor-selective peptidic prodrug of doxorubicin. Clin Cancer Res 14: 1256–1265.
11. Nomoto S, Hishita M, Inokawa Y, Takano N, Kanda M, et al. (2014) Expression Analysis of THOP1 in Background Laver, A Prognostic Predictive Factor in Hepatocellular Carcinoma, Extracted by Multiarray Analysis. Ann Surg Oncol.
12. Paschos G, Nomoto S, Hishita M, Inokawa Y, Takano N, Kanda M, et al. (2007) Characterization of thimet oligopeptidase and neurolysin activities in B16F10-Nex2 tumor cells and their involvement in angiogenesis and tumor growth. Mol Cancer 6: 44.
13. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, et al. (2005) The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11: 8326–8331.
14. Ferro ES, Tullai JW, Glickman MJ, Roberts JL (1999) Secretion of metalloendopeptidase 24.15 (EC 3.4.24.15) from canine placental tissue. J Biol Chem 274: 781–789.
15. Acker GR, Molneaux C, Orlovski M (1997) Syntapsosomal membrane-bound form of endopeptidase-24.15 generates Leu-enkephalin from dynorphin1–8, alpha- and beta-neoendorphin, and Met-enkephalin-Arg6-Gly7-Leu8. J Neurochem 48: 294–292.
16. Ferro ES, Tambourgi DV, Goborostaja F, Gomes MD, Sucupira M, et al. (2003) Secretion of a neuropetide-metalloenzyming enzyme similar to endopeptidase 22.19 by glioma C6 cells. Biochem Biophys Res Commun 191: 275–281.
17. Crack PJ, Wu TJ, Cummins PM, Ferro ES, Tullai JW, et al. (1999) The association of metalloendopeptidase EC 3.4.24.15 at the extracellular surface of the AT-20 cell plasma membrane. Brain Res 835: 113–124.
18. Shirrimpton CN, Smith AL, Lev RA (2002) Soluble metalloendopeptidases and neuroendocrine signaling. Endocr Rev 23: 647–664.
19. Ishihara K, Kamata M, Hayashi I, Yamashina S, Majima M (2002) Roles of bradykinin in vascular permeability and angiogenesis in solid tumor. Int Immunopharmacol 2: 899–909.
20. Hazei M, Amano H, Yoshida S, Kamata K, Kamata M, et al. (2002) Suppressed angiogenesis in kininogen-deficiencies. Lab Invest 82: 871–880.
21. Ikeda Y, Hayashi I, Kamoshita E, Yamazaki A, Endo H, et al. (2004) Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis. Breast Cancer Res Treat 85: 213–221.
22. Yang WH, Chang JT, Hsu SF, Li TM, Cho DY, et al. (2010) Bradykinin enhances cell migration in human chondrosarcoma cells through BK receptor signaling pathways. J Cell Biochem 109: 82–92.
23. Vamesu S (2008) Angiogenesis and tumor histologic type in primary breast cancer patients: an analysis of 155 needle core biopsies. Rom J Morphol Embryol 49: 181–186.

24. Vermeulen PB, van Golen KL, Dierix LY (2010) Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge. Cancer 116: 2748–2754.

25. Dubois V, Nieder M, Collot F, Negrouk A, Nguyen TT, et al. (2006) Thimet oligopeptidase (EC 3.4.24.15) activates CPI-0084Na, an extracellularly tumour-activated prodrug of doxorubicin. Eur J Cancer 42: 3049–3056.

26. Kessler JH, Khan S, Seifert U, Le Gall S, Chow KM, et al. (2011) Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol 12: 45–53.